Text Size

Toxicologic Pathology Forum: Current Status on the Use of Animal Models of Human Disease in the Pharmaceutical Industry in Japan in Nonclinical Safety Assessment-Opinion Paper

Tomohiro M., Okabe T., Kimura Y., Kinoshita K., Maeda M., Mitobe Y., Motoyama K., Yonezawa R., Sasaki S., Fujiwara M., Watanabe K.

  • 2019
  • Toxicologic Pathology
View publication
  • Technology


  • Affiliations

    Non-Clinical Evaluation Expert Committee, Drug Evaluation Committee, Pharmaceutical Manufacturers Association, Chuo-ku, Tokyo, Japan; Novartis Pharma K.K, Minato-ku, Tokyo, Japan; Wakamoto Pharmaceutical Co., Ltd, Ashigarakami, Kanagawa, Japan; Toyama Chemical Co., Ltd, Toyama, Japan; MSD K.K, Tokyo, Japan; Santen Pharmaceutical Co., Ltd, Ikoma, Nara, Japan; Torii Pharmaceutical Co., Ltd, Sakura, Chiba, Japan; Janssen Pharmaceutical K.K, Tokyo, Japan; Maruho Co., Ltd, Kyoto, Japan; AbbVie GK, Tokyo, Japan; Astellas Pharma Inc, Tsukuba, Ibaraki, Japan; Chugai Pharmaceutical Co., Ltd, Gotemba, Shizuoka, Japan

Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022